Q Li, Y Liu, Y Cheng, H Cao, K Du… - Drug Development …, 2025 - Wiley Online Library
Poor selectivity to tumor cells is a major drawback in the clinical application of the antitumor
drug docetaxel (DTX). Peptide–drug conjugates (PDCs) constructed by modifying antitumor …